Amedisys (NASDAQ:AMED) Lifted to “Buy” at Zacks Investment Research

Amedisys (NASDAQ:AMED) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday, January 12th. The firm currently has a $61.00 price objective on the health services provider’s stock. Zacks Investment Research‘s target price suggests a potential upside of 20.36% from the stock’s current price.

According to Zacks, “Over the past year, Amedisys has been trading above the broader industry. The company is currently exploring new opportunities in both Home Health and Hospice. At the Home Health division, the company witnessed a decline in Medicare revenues, while there was an improvement in non-Medicare revenues. At the Hospice division, the company registered strong growth across all segments. A favorable demographic trend and strategic acquisitions bode well for the company. On the flip side, escalating operating expenses and declining gross margin continue to raise concerns. Also, an intense competitive landscape and regulatory concerns continue to pose challenges in the home health and hospice industry.”

Several other analysts have also recently issued reports on the stock. BidaskClub cut shares of Amedisys from a “sell” rating to a “strong sell” rating in a research note on Thursday, January 11th. William Blair reiterated an “outperform” rating on shares of Amedisys in a research note on Tuesday, November 21st. SunTrust Banks reiterated a “buy” rating and issued a $70.00 target price on shares of Amedisys in a research note on Friday, November 10th. Robert W. Baird increased their target price on shares of Amedisys from $50.00 to $60.00 and gave the stock a “neutral” rating in a research note on Friday, November 10th. Finally, Craig Hallum reiterated a “buy” rating and issued a $68.00 target price (up from $55.00) on shares of Amedisys in a research note on Thursday, November 9th. One analyst has rated the stock with a sell rating, six have issued a hold rating and six have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $61.09.

Shares of Amedisys (NASDAQ:AMED) traded down $0.74 during mid-day trading on Friday, hitting $50.68. 332,835 shares of the company were exchanged, compared to its average volume of 321,331. The stock has a market cap of $1,745.03, a PE ratio of 40.54, a P/E/G ratio of 1.07 and a beta of 0.73. The company has a quick ratio of 1.33, a current ratio of 1.33 and a debt-to-equity ratio of 0.16. Amedisys has a 12 month low of $45.18 and a 12 month high of $65.91.

Several large investors have recently modified their holdings of the company. Federated Investors Inc. PA increased its holdings in shares of Amedisys by 2.3% in the 2nd quarter. Federated Investors Inc. PA now owns 1,929 shares of the health services provider’s stock worth $122,000 after buying an additional 44 shares during the last quarter. State Board of Administration of Florida Retirement System increased its holdings in shares of Amedisys by 0.5% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 19,658 shares of the health services provider’s stock worth $1,235,000 after buying an additional 93 shares during the last quarter. Suntrust Banks Inc. increased its holdings in shares of Amedisys by 4.3% in the 2nd quarter. Suntrust Banks Inc. now owns 5,702 shares of the health services provider’s stock worth $358,000 after buying an additional 237 shares during the last quarter. ETRADE Capital Management LLC grew its holdings in shares of Amedisys by 4.7% during the 2nd quarter. ETRADE Capital Management LLC now owns 6,409 shares of the health services provider’s stock valued at $403,000 after purchasing an additional 285 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Amedisys by 1.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,348 shares of the health services provider’s stock valued at $1,404,000 after purchasing an additional 410 shares during the last quarter. 94.97% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This story was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/05/zacks-investment-research-upgrades-amedisys-amed-to-buy.html.

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Get a free copy of the Zacks research report on Amedisys (AMED)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply